Trial Profile
The Comparative Analysis of the Effects on Plaque Volume and Tissue Characteristics Between Combined Therapy With STAatin Plus FENOfibrate and Statin Alone in Mild to Moderate, Non- Intervened Coronary Artery Stenosis (STAFENO Trial)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Fenofibrate (Primary) ; Rosuvastatin
- Indications Coronary artery disease
- Focus Therapeutic Use
- Acronyms STAFENO
- Sponsors Daewoong Pharmaceutical
- 16 May 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2020.
- 12 May 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2020.
- 12 May 2019 Planned number of patients changed from 160 to 106.